Lv1
20 积分 2024-10-24 加入
DLBCL: Who is high risk and how should treatment be optimized?
2小时前
待确认
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
2个月前
已完结
Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial
3个月前
已完结
A comeback for checkpoint inhibition in multiple myeloma
3个月前
已完结
Transplantation in Adult Patients with Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis: Yes or No?
5个月前
已完结
Transplantation in Adult Patients with Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis: Yes or No?
5个月前
已关闭
Transplantation in Adult Patients with Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis: Yes or No?
5个月前
已关闭
皖公网安备34019202002308
